Alembic Pharmaceuticals Secures FDA Approval for Generic Levothyroxine Sodium Tablets in $1.87 Billion Market
核心洞察
Alembic Pharmaceuticals Limited received final FDA approval for its generic Levothyroxine Sodium Tablets USP across 12 different strengths from 25 mcg to 300 mcg.
The approved product is therapeutically equivalent to AbbVie's Synthroid and is indicated for treating hypothyroidism (搜索) and as adjunct therapy in thyroid cancer (搜索) management.
According to IQVIA data, the product represents an estimated US market size of $1.869 billion for the 12 months ending March 2026.
Alembic Pharmaceuticals Limited has secured final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP, marking a significant milestone in the company's expansion into the lucrative US generics market. The approval covers 12 different strengths ranging from 25 mcg to 300 mcg, positioning the company to compete in a market valued at nearly $1.87 billion.
Therapeutic Equivalence and Clinical Applications
The approved product is therapeutically equivalent to Synthroid, the reference listed drug marketed by AbbVie Inc. According to the company's regulatory filing, the approval covers Levothyroxine Sodium Tablets USP in strengths of 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg.
Levothyroxine sodium tablets are indicated as replacement therapy in primary, secondary and tertiary congenital or acquired hypothyroidism (搜索). The medication also serves as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer (搜索).
Market Opportunity and Financial Impact
According to IQVIA data for the 12 months ending March 2026, the product has an estimated US market size of $1.869 billion, making it a significant addition to Alembic's US generics portfolio. This substantial market opportunity reflects the widespread prevalence of hypothyroidism (搜索) and the critical role of levothyroxine therapy in patient management.
Regulatory Portfolio Expansion
With this latest approval, Alembic now holds a cumulative total of 239 ANDA approvals from the USFDA (搜索), comprising 220 final approvals and 19 tentative approvals. This milestone further strengthens the company's presence in the highly competitive US pharmaceutical market.
Company Background and Manufacturing Capabilities
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company established in 1907 that manufactures and markets generic pharmaceutical products globally. The company's research and manufacturing facilities have received approval from several international regulatory authorities, including the USFDA (搜索).
According to the company, Alembic is among the leading branded generic pharmaceutical companies in India, with its products marketed through a field force of over 5,500 professionals. This extensive commercial infrastructure positions the company well to leverage its growing portfolio of FDA-approved products in both domestic and international markets.